Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    Ambrisentan and Tadalafil | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
Condition: Hypertension, Pulmonary
Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose;   Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
2 Recruiting Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Other: no intervention, only observation of different groups

Indicates status has not been verified in more than two years